

Supplemental Figure 1: Titration of serum to define optimal concentrations for CDC

CHO-S cells expressing the R-4d construct were opsonised with either 10µg/mL rituximab (RTX) or an isotype control (ISO) before incubating with different concentrations of human serum (v/v) for 30 minutes at 37°C. CDC was measured by flow cytometry using propidium iodide inclusion as a measure of cell lysis. The mean and range of duplicates from a single experiment are presented.







Supplemental Figure 2: Expression and targeting of CD52 constructs

A) CHO-S cells expressing either C-flush or human CD52 were labelled with CFSE and CAMPATH-1H before use as targets in an ADCP assay. The mean and range of two independent experiments are presented. Statistical significance was assessed by a two-way ANOVA, ** p <0.005. B) Expression profiles for CHO-S cells expressing CD52-NQ, CD52 or C-flush analysed by flow cytometry 24h after transfection. C) Expression profiles for CHO-S cells expressing C-GPI or CD52 24h after transfection. Panel B) and C) are independent transfections.



Supplemental Figure 3: Lack of complement defence molecules on A20 cells.

A20 cells expressing R-flush or R-8d constructs were assessed by flow cytometry for the presence or absence of complement defence molecules using antibodies towards CD55 and CD59